SCHEDULE 13G/A: RTW Investments Discloses Significant 9.99% Stake in Neurogene Inc.

RTW Investments, LP and Roderick Wong, M.D. have filed an amended Schedule 13G, reporting a 9.99% beneficial ownership stake in Neurogene Inc.'s common stock as of December 31, 2024.

Summary

• RTW Investments, LP and Roderick Wong, M.D. (collectively, the "Reporting Persons") have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Neurogene Inc. (the "Company").
• As of December 31, 2024, the Reporting Persons beneficially own an aggregate of 1,498,829 shares of Neurogene Inc. Common Stock.
• This ownership represents 9.99% of the Company's outstanding Common Stock.
• The calculation of the percentage is based on 14,854,725 shares outstanding as of November 13, 2024, as reported in the Company's Quarterly Report on Form 10-Q filed on November 18, 2024.
• The reported beneficial ownership includes the assumed exercise of 148,573 warrants held by the Reporting Persons, which is the maximum amount exercisable without exceeding the 9.99% beneficial ownership cap.
• RTW Investments, LP is a Delaware limited partnership and an investment adviser to certain funds (the "RTW Funds"), which directly hold the shares.
• Roderick Wong, M.D. is the Managing Partner and Chief Investment Officer of RTW Investments.
• The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While a Schedule 13G is a factual disclosure, a significant stake by a reputable institutional investor like RTW Investments can be viewed favorably by the market, suggesting confidence in the company.

Positives

• The disclosure of a significant 9.99% stake by an institutional investor like RTW Investments, LP, and its Managing Partner, Roderick Wong, M.D., can signal confidence in Neurogene Inc.'s long-term prospects.
• Institutional ownership often provides a level of stability and professional oversight to a company's shareholder base.

Future Outlook

No forward-looking statements or guidance from Neurogene Inc. are provided in this beneficial ownership filing. The document solely reports a historical ownership position.

Management Comments

• Roderick Wong, M.D., Managing Partner of RTW Investments, LP, certified that 'to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.'

Industry Context

This filing reflects a significant institutional investment in a biotechnology company, Neurogene Inc. Such substantial stakes by specialized investment firms like RTW Investments are common in the biotech and pharmaceutical sectors, often indicating a strategic long-term view on the company's pipeline or market potential.

Comparison to Industry Standards

• Not applicable for direct comparison of company performance or projects, as this filing pertains to beneficial ownership.
• Significant institutional ownership stakes, such as the 9.99% reported by RTW Investments, are common in the biotechnology sector, indicating investor interest and often a belief in the company's future growth or therapeutic advancements.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may positively influence investor perception and potentially the stock price, signaling institutional confidence.
• Company Management: Increased institutional ownership may lead to greater scrutiny or engagement from the investor, though the filing states the purpose is not to influence control.

Key Dates

Keywords

Neurogene Inc., RTW Investments, Roderick Wong, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investment, Biotechnology, Healthcare, SEC Filing